Shorter rifampicin treatment for less severe tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a shorter treatment using the drug rifampicin is as good as the usual longer treatment for people with less severe tuberculosis (TB). If you join, you'd get a shorter course of pills, which might be more convenient and have fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old
- Have a positive sputum test showing you have TB that is sensitive to standard medicines
- Have a milder or less extensive form of TB (your doctor can check this)
- Have your HIV status checked or known
- Be well enough to be treated at home (not in the hospital)
- Not have taken more than a week of TB treatment for this current episode
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This study tests whether a shorter course of TB treatment (4 months) works just as well as the standard longer course (6 months) for people whose chest X-ray suggests TB but whose sputum test does not confirm it. It aims to reduce treatment burden while keeping the cure rate high.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Pulmonary TB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.